NeoGenomics Inc (NEO)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at NeoGenomics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 15.30 $ — 95% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 12.6% failed
- More than 10% revenue growth is expected for the coming year 10.0% passed
- Share count grows by less than 3% a year 1.0% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 7.1% failed
- Gross margin at 40% or higher and without meaningful erosion 38.9% failed
- Goodwill from acquisitions does not grow faster than revenue 38.6% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 285 m passed
- Return on capital at 15% or higher, or up versus two years ago -5.2% failed
- Insiders hold at least 10% or are net buyers 2.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 28.9% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 12
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.18 | 0.16 – 0.20 | 804 | 52.3% | 11 |
| 12/31/2027 | 0.34 | 0.28 – 0.41 | 885 | 85.1% | 11 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.05 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.60 | – | 172 | 10.60 | -8.90 | 10 | -2 |
| 2025: Q1 | -1.02 | – | 168 | 7.50 | -15.40 | -25 | -30 |
| 2025: Q2 | -1.76 | – | 181 | 10.20 | -24.90 | 20 | 14 |
| 2025: Q3 | -1.06 | – | 188 | 11.90 | -14.40 | 9 | 1 |
| 2025: Q4 | -0.38 | – | 190 | 10.60 | -5.20 | 1 | -7 |
| 2026: Q1 | -0.66 | – | 187 | 11.10 | -9.20 | -8 | -13 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 244 | 3 | -6 | -0.08 | 21 | 187 | 337 |
| 2017 | 240 | 3 | 0 | -0.02 | 18 | 206 | 343 |
| 2018 | 277 | 10 | 3 | 0.14 | 45 | 320 | 505 |
| 2019 | 409 | 13 | 8 | 0.39 | 23 | 507 | 710 |
| 2020 | 444 | -14 | 4 | 0.19 | 1 | 694 | 988 |
| 2021 | 484 | -119 | -8 | -0.35 | -27 | 1,108 | 1,870 |
| 2022 | 510 | -158 | -144 | -5.81 | -66 | 998 | 1,740 |
| 2023 | 592 | -108 | -88 | -3.50 | -2 | 942 | 1,681 |
| 2024 | 661 | -92 | -79 | -3.11 | 7 | 902 | 1,638 |
| 2025 | 727 | -66 | -108 | -4.22 | 5 | 837 | 1,360 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
NeoGenomics, Inc. betreibt ein Netzwerk krebsspezialisierter Testlabore in den USA und Großbritannien.
| Employees | 2,500 |
|---|---|
| Headquarters | Fort Myers, FL |
| Address | 9490 NeoGenomics Way, 33912 Fort Myers, United States |
| Phone | 239 768 0600 |
| Website | neogenomics.com |
| IPO Date | 2. Nov 1999 |
| ISIN | US64049M2098 |
| Stock Split | 1:100 on 04/16/2003 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Anthony P. Zook | CEO & Director | 1961 |
| Warren Stone | President & COO | 1973 |
| Elizabeth A. Floegel | Chief Digital & Information Officer | 1976 |
| Alicia C. Olivo | Executive VP of Business Development, General Counsel & Corporate Secretary | 1984 |
| Gary Passman | Chief People & Culture Officer | – |
| Abhishek Jain | Executive VP & CFO | 1976 |
| Gregory D. Aunan | Senior VP & Chief Accounting Officer | 1969 |
| Kendra Sweeney | Vice President of Investor Relations & Communications | – |
| Clarence Cooper Esq. | Vice President of Compliance & Privacy | – |
| Andrew A. Lukowiak Ph.D. | Chief Innovation Officer | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.